Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 14.83% |
| A M R CP | AAMRQ | 7.91% |
| OLD SECOND B | OSBC | 6.73% |
| SANTARUS INC | SNTS | 6.32% |
| JAZZ PHARMAC | JAZZ | 6.17% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Reuters reported that MetLife Inc. ( MET - Analyst Report ) has vended senior unsecured notes worth $750 million. The notes bear an interest rate of 4.125% and are scheduled to mature in February 15, 2042.
MetLife expects to utilize the funds raised from the issuance of these notes for business operations and to retire senior notes worth $750 million that are due to mature in August and November of 2013.
Additionally, the 30-year notes carry a rating of “a3” from Moody’s Investor Service of Moody’s Corp. ( MCO - Analyst Report ) and “A-” from A.M. Best Co., Fitch Ratings and Standards & Poor’s (S&P). The outlook for all ratings remains stable.
Rating Agencies Approve New Debt
Earlier in May this year, S&P had upgraded its outlook on MetLife’s debt to stable from negative, while affirming all the long-term counterparty credit ratings of the company and its operating subsidiaries. The rating agency also upgraded the ratings of MetLife’s American Life Insurance Co.(ALICO) in Asia, which was acquired from American International Group Inc. ( AIG - Analyst Report ) in November 2010. In the same month, Fitch had also affirmed its rating on the company.
The ratings from all these agencies validate MetLife’s solid earnings growth and escalated its operational scale on the heels of exceptional operating performance from its diversified business basket and brand appreciation. Moreover, efficient management of the company’s investment portfolio and enterprise risk has helped it secure competitive advantage in the market.
Despite the lingering concerns regarding the low interest rate and economic volatility, MetLife has been successfully maintaining acceptable risk-based adjusted capital (RBC) ratios. Further, the latest notes sale is not expected to hamper the financial leverage that stood at 27% at the end of June 2012, which is still higher given the lower capital in 2012 compared with 2011, primarily led by alterations in DAC accounting standards this year. Conversely, the debt leverage is expected to improve to about 24% by the end of 2013, when MetLife will have paid off the debts that are scheduled to mature next year.
Additionally, S&P anticipates MetLife to produce net retained earnings of about $3.9 billion and $4.2 billion in 2012 and 2013, respectively. This estimate includes the remarketing and settlement of equity units worth $1 billion, in both 2012 and 2013. The rating agency estimates EBITDA in the band of $9-10 billion with EBITDA fixed-charge coverage of 6.5x to 7x.
Meanwhile, Fitch elucidated the possibility of a rating upgrade provided MetLife maintains the NAIC RBC ratio above 450%, debt-equity ratio lower than 25%, interest coverage ratio is in the band of 8x-10x and successfully integrate ALICO.
On the flip side, the ratings could be downgraded if NAIC RBC ratio falls below 350%, debt-equity ratio more than 30% and interest coverage ratio dips below 5x in future.
Earnings Recap
MetLife reported second-quarter 2012 operating earnings per share of $1.33, smoothly outpacing both the Zacks Consensus Estimate of $1.25 and year-ago quarter’s earnings of $1.13. Operating earnings escalated 18% year over year to $1.43 billion. Total operating revenue for the reported quarter edged up 1% year over year to $16.79 billion and also exceeded the Zacks Consensus Estimate of $16.54 billion.
The upbeat results were primarily due to a robust earnings growth across U.S., Asia and EMEA along with improved underwriting results, higher net investment income, higher-than-expected derivative gains as well as lower-than-expected operating expenses. This was partially offset by lower-than-expected top-line growth across the U.S. and EMEA, particularly led by low premiums’ growth and continued underperformance from variable annuities as well as low interest rate environment.
We retain our long-term 'Neutral' recommendation on MetLife. The quantitative Zacks #3 Rank (short-term Hold rating) for the company indicates no clear directional pressure on the stock over the near term.
Read the full reports :
Analyst Report on AIG
Analyst Report on MET
Analyst Report on MCO